A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia

Journal of Clinical Psychiatry

Volumn 67, Issue 7, 2006, Pages 1114-1123

  Ascher Svanum, Haya ^a   Zhu, Baojin ^a   Faries, Douglas ^a   Lacro, Jonathan P ^b   Dolder, Christian R ^c  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WINGATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ILLICIT DRUG; NEUROLEPTIC AGENT;

ALCOHOL CONSUMPTION; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DIABETES MELLITUS; DRUG USE; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; SOCIAL ASPECT; SYMPTOMATOLOGY; WEIGHT GAIN;

EID: 33747194086     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v67n0715     Document Type: Article

References (43)

1. American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. 2nd ed. Am J Psychiatry 2004;161 (suppl 2):1-56
2. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63:892-909
3. Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv 1998;49:196-201
4. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-639
5. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891
6. Marder SR. Overview of partial compliance. J Clin Psychiatry 2003;64(suppl 16):3-9
7. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-175
8. Owen RR, Fischer EP, Booth BM, et al. Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996;47:853-858
9. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-222
10. Linden M, Godemann F, Gaebel W, et al. A prospective study of factors influencing adherence to a continuous neuroleptic treatment program in schizophrenia patients during 2 years. Schizophr Bull 2001;27:585-596
11. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106:286-290
12. Weiss KA, Smith TE, Hull JW, et al. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002;28:341-349
13. Vitolins MZ, Rand CS, Rapp SR, et al. Measuring adherence to behavioral and medical interventions. Control Clin Trials 2000;21(suppl 5):188S-194S
14. Velligan DI, Lam F, Ereshefsky L, et al. Psychopharmacology: perspec-tives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-667
15. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
16. Zhao Z, Tunis SL, Lage M. Medication treatment patterns following initiation on olanzapine versus risperidone. Clin Drug Invest 2002;22:741-749
17. Al-Zakwani IS, Barron JJ, Bullano MF, et al. Analysis of healthcare utilization patterns and adherence in patients receiving typical and atypical antipsychotic medications. Curr Med Res Opin 2003;19:619-626
18. Gibson PJ, Damler R, Jackson EA, et al. The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population. Value Health 2004;7:22-35
19. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699
20. Valenstein M, Blow FC, Copeland LA, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophr Bull 2004;30:255-264
21. Dolder CR, Lacro JP, Jeste DV. Adherence to antipsychotic and nonpsychiatric medications in middle-aged and older patients with psychotic disorders. Psychosom Med 2003;65:156-162
22. Ascher-Svanum H, Paries DE, Zhu B, et al. Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry 2006;67:453-460
23. Lehman AF, Fischer EP, Postrado L. The Schizophrenia Care and Assessment Program Health Questionnaire (SCAP-HQ): an instrument to assess outcomes of schizophrenia care. Schizophr Bull 2003;29:247-256
24. Ascher-Svanum H, Zhu B, Faries D, et al. Time to all-cause discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8. Available at: http://www.biomedcentral.com/content/pdf/1471-244x-6-8.pdf
25. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-276
26. Davis JM, Chen N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757-771
27. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389
28. Frances A, Pincus HA, First MB. The Global Assessment of Functioning Scale (GAF). Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
29. Psychopharmacology Research Branch, National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:534-537
30. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
31. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia [letter]. Arch Gen Psychiatry 1982;39:486-487
32. Graham P, Bull B. Approximate standard errors and confidence intervals for indices of positive and negative agreement. J Clin Epidemiol 1998;51:763-771
33. Walsh E, Gilvarry C, Samele C, et al, UK700 Group. Predicting violence in schizophrenia: a prospective study. Schizophr Res 2004;67:247-252
34. Blomhoff S, Seim S, Friis S. Can prediction of violence among psychiatric inpatients be improved? Hosp Community Psychiatry 1990;41:771-775
35. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797
36. Gaebel W, Pietzcker A. One-year outcome of schizophrenic patients: the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 1985;18:235-239
37. Gardner W, Lidz CW, Mulvey EP, et al. Clinical versus actuarial predictions of violence of patients with mental illnesses. J Consult Clin Psychol 1996;64:602-609
38. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005;133:129-133
39. Karow A, Lambert M, Czekalla J, et al. Correlations of subjective well-being with compliance. World J Biol Psychiatry 2005;6(suppl 1):225
40. Nose M, Barbui C, Tansella M. How often do patients with psychosis fail to adhere to treatment programmes? a systematic review. Psychol Med 2003;33:1149-1160
41. Pan PC, Tantam D. Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 1989;79:564-570
42. Cuffel BJ, Alford J, Fischer EP, et al. Awareness of illness in schizophrenia and outpatient treatment adherence. J Nerv Ment Dis 1996;184:653-659
43. Svarstad BL, Shireman TI, Sweeney JK. Using drug claims data to assess the relationship of medication adherence with hospitalization and costs. Psychiatr Serv 2001;52:805-811